Search

Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

Read more

EHA-BSH joint membership

Save money and time by becoming a joint member of EHA and the British Society of Haematology. We've joined forces with the British Society of Haematology (BSH) to offer a special joint membership deal.

Read more

EHA-SEHH joint membership

Save money and time by becoming a joint member of EHA and the Sociedad Española de Hematología y Hemotherapia. We've joined forces with the Sociedad Española de Hematología y Hemotherapia (SEHH) to offer a special joint membership deal.

Read more

EHA-SIE joint membership

Save money and time money by becoming a joint member of EHA and the Società Italiana di Ematologia. We've joined forces with the Società Italiana di Ematologia (SIE) to offer a special joint membership deal.

Read more

EHA-SSH joint membership

Save money and time by becoming a joint member of EHA and the Swiss Society of Hematology. We've joined forces with the Swiss Society of Hematology (SSH) to offer a special joint membership deal.

Read more

EHA-SPSHTM joint membership

Save money and time by becoming a joint member of EHA and the Scientific and Practical Society of Hematologists and Transfusiologists from the Republic of Moldova.

Read more

Lighting the Flame program phases

A full guide to what our Lighting the Flame program involves, including dates of upcoming online workshops and in-person retreats.

Read more

Targeting the B-cell Receptor in Aggressive B-cell Lymphomas

In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.

Read more